Highlights from the ASGCT 23rd Annual Meeting
First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A: Safety and FVIII Activity Results
Steven Pipe1, Charles R. M. Hay2, John P. Sheehan3, Toshko Lissitchkov4, Elke Detering5, Silvia Ribeiro5, Konstantina Vanevski5
1University of Michigan, Ann Arbor, MI
2University Dept of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
3Department of Medicine, University of Wisconsin–Madison, Madison, WI
4National Specialized Hospital for Active Treatment of Haematologic Diseases, Sofia, Bulgaria
5Bayer, Basel, Switzerland
Key Data Points
Inclusion criteria and escalating dosing regimen for the phase 1/2 open-label safety and dosing-finding study for AAVhu37 capsid vector in severe hemophila A. Two patients have been enrolled in cohorts 1, 2, and 3. Results for the first 2 cohorts were available for this presentation. (PTP, previously treated patients; ED, exposure days; GC, gene copies)
FVIII activity results for the 2 patients in cohort 1 showed sustained expression of FVIII in both patients for > 12 months. At this lowest dose, 1 patient (right panel) achieved clinically meaningful FVIII levels resulting in a reduction in the number of bleeds over 12 months from 99 to 4.
RELATED CONTENT
Interactive Webinars
Presented by Barbara A. Konkle, MD
Presented by Steven W. Pipe, MD
Presented by Johnny Mahlangu, BSc, MBBCh, MMed, FCPath
Presented by David Lillicrap, MD
Presented by Thierry VandenDriessche, PhD
Presented by Flora Peyvandi, MD, PhD
Presented by Glenn F. Pierce, MD, PhD
